Denodo Adds to Executive Team with Key Appointments: Daniel Lender Joins as Chief Financial Officer and Stephen Welles as Chief Legal Officer
Denodo, a leader in data management, today announced two key additions to its executive team to help to guide Denodo through its next phase of growth: Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer. Mr. Lender and Mr. Welles will lead all of Denodo’s global financial and legal strategy and operations, reporting directly to Denodo’s Chief Executive Officer, Angel Viña.
“We’re excited to welcome Daniel as our new CFO and Stephen as our new CLO,” said Angel Viña, CEO and Founder of Denodo. “Daniel brings extensive financial and operational experience in enterprise software to our executive team and Stephen adds his broad and deep expertise in legal matters. These two key appointments strengthen our executive team and will be a great asset to Denodo as we continue to grow our global business.”
Daniel Lender is the newest addition to Denodo’s executive leadership team and brings more than 30 years of enterprise software and financial markets experience to his role. Mr. Lender joins Denodo after a long tenure with QAD Inc., a leading provider of next generation manufacturing and supply chain management solutions in the cloud, where he served as executive vice president and chief financial officer.
“I am absolutely thrilled to join Denodo at this stage,” said Daniel Lender. “With data growing at an exponential rate and multi-cloud platforms becoming the norm, I believe Denodo, with its unique and proprietary platform, is well positioned to continue its growth path and help its customers unlock value from their data. I look forward to working with the Denodo leadership team to help fuel Denodo’s next phase of growth.”
Stephen Welles brings more than 25 years of experience to his new position as Chief Legal Officer. He joined Denodo from Wilson Sonsini Goodrich & Rosati, the premier legal advisor to technology, life sciences, and other growth enterprises worldwide, where he was a senior counsel. Before that, he was the senior vice president and general counsel at Oplink Communications, an optical networking equipment company with more than 3,000 employees worldwide.
“Denodo has a bright future and I am excited to be a part of the team,” said Stephen Welles. “Denodo’s mission to help enterprises become data-driven organizations is an important one, and it will continue to drive Denodo’s growth.”
Denodo was recognized as a Leader in the 2022 Gartner® Magic Quadrant™ for Data Integration Tools for a third year in a row, and in the Forrester Wave™: Enterprise Data Fabric, Q2 2022 for a second year in a row. Denodo is the fastest growing vendor among the top 10 data integration vendors according to Gartner Market Share Analysis: Data Integration Software, Worldwide, 2021. Denodo also has been consistently receiving Customers’ Choice distinction in the Gartner Peer Insights 'Voice of the Customer': Data Integration Tools report for the last two years, showcasing how positively Denodo customers perceive the value of the product, services and support offered by Denodo.
Please tweet: News: @denodo adds to executive team - Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer to drive next phase of growth for #datamanagement and #dataintegration leader
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005616/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom